{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:35:47Z","timestamp":1793241347555,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40265-017-0752-y","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T05:31:38Z","timestamp":1493875898000},"page":"1029-1034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Niraparib: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"issue":"8","key":"752_CR1","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","volume":"58","author":"P Jones","year":"2015","unstructured":"Jones P, Wilcoxen K, Rowley M, et al. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem. 2015;58(8):3302\u201314.","journal-title":"J Med Chem"},{"issue":"2","key":"752_CR2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40265-016-0688-7","volume":"77","author":"G O\u2019Sullivan Coyne","year":"2017","unstructured":"O\u2019Sullivan Coyne G, Chen AP, Meehan R, et al. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77(2):113\u201330.","journal-title":"Drugs."},{"key":"752_CR3","unstructured":"Tesaro. Tesaro announces expanded development program for niraparib focused on the treatment of front-line metastatic ovarian and lung cancer and metastatic breast cancer. 2017. http:\/\/www.tesarobio.com . Accessed 3 Apr 2017."},{"key":"752_CR4","unstructured":"Tesaro. ZEJULA\u2122 (Niraparib): US prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/ . Accessed 29 Mar 2017."},{"key":"752_CR5","unstructured":"European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. 2016. http:\/\/www.ema.europa.eu . Accessed 3 Apr 2017."},{"key":"752_CR6","unstructured":"Tesaro. Tesaro announces acceptance for review of niraparib marketing authorization by EMA. 2016. http:\/\/tesarobio.com . Accessed 3 Apr 2017."},{"issue":"22","key":"752_CR7","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1021\/jm901188v","volume":"52","author":"P Jones","year":"2009","unstructured":"Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009;52(22):7170\u201385.","journal-title":"J Med Chem"},{"issue":"13","key":"752_CR8","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.18632\/oncotarget.2083","volume":"5","author":"KA Bridges","year":"2014","unstructured":"Bridges KA, Toniatti C, Buser CA, et al. Niraparib (MK-4827), a novel poly(ADP-ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014;5(13):5076\u201386.","journal-title":"Oncotarget."},{"issue":"3","key":"752_CR9","first-page":"755","volume":"33","author":"S Mueller","year":"2013","unstructured":"Mueller S, Bhargava S, Molinaro AM, et al. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res. 2013;33(3):755\u201362.","journal-title":"Anticancer Res"},{"issue":"6","key":"752_CR10","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s10637-011-9770-x","volume":"30","author":"L Wang","year":"2012","unstructured":"Wang L, Mason KA, Ang KK, et al. MK-4827, a PARP-1\/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012;30(6):2113\u201320.","journal-title":"Invest New Drugs"},{"key":"752_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0451-2","author":"L Andel van","year":"2017","unstructured":"van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs. 2017. doi: 10.1007\/s10637-017-0451-2 .","journal-title":"Invest New Drugs"},{"issue":"22","key":"752_CR12","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"key":"752_CR13","doi-asserted-by":"crossref","unstructured":"Gonzalez-Martin A, Backes FJ, Baumann KH, et al. A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy [abstract no. TPS5606]. J Clin Oncol. 2016;34(Suppl.).","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5606"},{"key":"752_CR14","doi-asserted-by":"crossref","unstructured":"Moore KN, Rimel B, Agarwal S, et al. A Phase 2, open label study of niraparib in women with advanced, relapsed, highgrade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after 3 previous chemotherapy regimens [abstract no. TPS5609]. J Clin Oncol. 2015;33(Suppl. 1).","DOI":"10.1200\/jco.2015.33.15_suppl.tps5609"},{"key":"752_CR15","doi-asserted-by":"crossref","unstructured":"Balmana J, Tryfonidis K, Audeh W, et al. A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician\u2019s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study) [abstract no. OT1-03-05]. Cancer Res. 2016;76(4 Suppl. 1).","DOI":"10.1158\/1538-7445.SABCS15-OT1-03-05"},{"key":"752_CR16","doi-asserted-by":"crossref","unstructured":"Mirza MR, Mortensen CE, DePont Christensen R, et al. A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: the ENGOT-OV24\/AVANOVA1 trial [abstract no. 5555]. J Clin Oncol. 2016;34(Suppl.).","DOI":"10.1200\/JCO.2016.34.15_suppl.5555"},{"key":"752_CR17","doi-asserted-by":"crossref","unstructured":"Mirza MR, Mortensen CE, Avall-Lundqvist E, et al. ENGOT-OV24-NSGO\/AVANOVA: niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinumsensitive epithelial ovarian, fallopian tube, or peritoneal cancer [abstract no. TPS5607]. J Clin Oncol. 2015;33(Suppl. 1).","DOI":"10.1200\/jco.2015.33.15_suppl.tps5607"},{"key":"752_CR18","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos P, Moore KN, Sachdev JC, et al. Phase I\/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162) [abstract no. TPS5599]. J Clin Oncol. 2016;34(Suppl.).","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5599"},{"key":"752_CR19","doi-asserted-by":"crossref","unstructured":"Flores JP, Mathew P. Combination therapy with enzalutamide and the poly (ADPribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202 [abstract no. TPS5095]. J Clin Oncol. 2016;34(Suppl.).","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5095"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0752-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T03:14:00Z","timestamp":1569208440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0752-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0752-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}